USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: Enslein Research, Inc.
Address: 183 East Main Street
Suite 1428
Rochester, NY 14604
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (585) 232-8160

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $351,207.00 6
SBIR Phase II $1,110,379.00 3

Award List:

PHASE I SAR ESTIMATION OF SKIN AND EYE IRRITATION

Award Year / Program / Phase: 1983 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kurt Enslein
Award Amount: $47,283.00

SAR ESTIMATION OF CARCINOGENESIS BIOASSAY RESULTS.

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kurt Enslein , President
Award Amount: $50,000.00

PHASE I SAR ESTIMATION OF SKIN AND EYE IRRITATION

Award Year / Program / Phase: 1985 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kurt Enslein
Award Amount: $450,000.00
Abstract:
This proposal deals with the developmentof structure activity equations (models) for the draize skin and eye irritancy tests. the applicant has previously developed such models for rat oral ld(50), mutagenicity, carcinogenicity, teratogenicity, and biodegradability. the principles used in the… More

SAR ESTIMATION OF CARCINOGENESIS BIOASSAY RESULTS.

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kurt Enslein , President
Award Amount: $249,000.00
Abstract:
The purpose of this application is to develop structure-activity models of the nci/ntp and other carcinogenesis bloassays. through these models it would become possible to predict the probability of carcinogenicity of untested compounds. the application would be to those chemicals that have not as… More

DEVELOPMENTAL TOXICOLOGY STRUCTURE-ACTIVITY EQUATIONS

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kurt enslein
Award Amount: $50,000.00
Abstract:
Recent assessments of the status of developmental toxicologyby the regulatory and scientific communities have identifieda need to apply structure-activity relationships (sars) to existing test strategies. health designs, inc. has developed a statistical sar model of teratogenicity based on the… More

INVESTIGATION OF 3-DIMENSIONAL PARAMETERS FOR SAR MODELLING OF MUTAGENICITY

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
In this research we will investigate the applicability of 3-dimensional parameters to the structure-activity modellingof mutagenicity. the mutagenic endpoints will be the ames test, and either the mouse lymphoma or the syrian hamster ovary cell assay. the parameters to be investigated will include… More

Computer Assisted Methods In Predictive Toxicology

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vijay K. Gombar
Award Amount: $50,000.00
Abstract:
The list of chemicals for which no toxicity data exist is ballooning. This requires both federal regulatory agencies and industry to explore new rapid and cost-effective methods for assessing health hazards and environmental effects of chemicals, especially since the resources are scarce and risk… More

QSAR Models: Human CYP450 Drug Metabolism and Kinetics

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kurt N. Enslein
Award Amount: $103,924.00
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of the proposed research is to provide computer-based tools to aid in the high-throughput screening of drug candidates, derived from combinatorial chemistry and similar techniques. The data for the QSAR models will be derived from human… More

QSAR Models: Human CYP450 Drug Metabolism and Kinetics

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kurt N. Enslein
Award Amount: $411,379.00
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of the proposed research is to provide computer-based tools to aid in the high-throughput screening of drug candidates, derived from combinatorial chemistry and similar techniques. The data for the QSAR models will be derived from human… More